Matter Bio Announces FDA Clearance of IND Application for LM-LLO-TT in Pancreatic Ductal Adenocarcinoma

FDA clearance enables initiation of first-in-human Phase 1/2a clinical trial evaluating LM-LLO-TT, Matter Bio's attenuated Listeria monocytogenes-based immunotherapy candidate. SAN FRANCISCO, June 10, 2026 /PRNewswire/ -- Matter Bio, a biotechnology company developing next-generation...